Dr. Overman Discusses ReDOS Study in mCRC

preview_player
Показать описание
Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Dr. Overman Discusses 0:02:15

Dr. Overman Discusses ReDOS Study in mCRC

Dr. Overman Discusses 0:01:15

Dr. Overman Discusses Progress With Immunotherapy in GI Cancer

Dr. Overman on 0:01:29

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

Dr. Overman Discusses 0:02:32

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

Dr. Overman on 0:01:18

Dr. Overman on Unmet Needs With Immunotherapy in mCRC

The First Oral 0:04:54

The First Oral Fluoropyrimidine for mCRC—TAS-102

The Optimal Dosing 0:08:18

The Optimal Dosing Strategy for Regorafenib in mCRC

Debate: Is there 0:09:06

Debate: Is there an optimal treatment for refractory colorectal cancer? - TAS-102 or regorafenib

Epilepsy Tools, Strategies 1:19:31

Epilepsy Tools, Strategies & Resources

Sequencing of Therapy 0:04:26

Sequencing of Therapy in Refractory mCRC

Jeffrey A. Meyerhardt, 0:01:01

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

Efficacy of TAS-102 0:01:12

Efficacy of TAS-102 Continues to Hold Up in Metastatic CRC and Gastric Cancers

David MacMillan: A 0:02:03

David MacMillan: A “flashlight” to identify cellular proteins for drug discovery

Dr. Kasi talks 0:48:22

Dr. Kasi talks with Scientific Director Manju George

Synthesis Workshop: Syntheses 0:19:36

Synthesis Workshop: Syntheses of Macfarlandin C + Dendrillolide A with Dr. Tyler Allred (Episode 40)

Achieving a Durable 0:06:49

Achieving a Durable Response With Regorafenib in mCRC

Nevena Damjanov, MD, 0:00:36

Nevena Damjanov, MD, on the outcomes of combining atezolizumab with bevacizumab in HCC patients

The Culture of 1:17:37

The Culture of Trauma Coverage Before and After the Internet

Lunch and Learn: 1:01:21

Lunch and Learn: Updates in Colorectal Cancer

Billy Graham Religious 0:04:06

Billy Graham Religious Interpreting

Howard Hochster, MD, 0:02:07

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

Tanios Bekaii-Saab, MD 0:01:30

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

David W.C. MacMillan: 0:32:44

David W.C. MacMillan: Nobel Prize lecture in chemistry 2021

CCHF VS 11.1 0:22:25

CCHF VS 11.1 - Prof. David Nagib | C–H Functionalization via Radical Relay Chaperones